WALTHAM, Mass., June 30, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that it has priced an underwritten public offering of an aggregate of 4,650,000 shares of its common stock at an offering price to the public of $81.00 per share. The gross proceeds from the offering will be approximately $376.7 million. In addition, TESARO has granted the underwriters an option to purchase up to an additional $56.5 million of its common stock. TESARO estimates that the net proceeds from the offering will be approximately $355.6 million after deducting the underwriting discount and other offering expenses payable by TESARO, but excluding any exercise of the underwriters’ option.

The offering is expected to close on or about July 7, 2016, subject to customary closing conditions. Citigroup, Leerink Partners, Credit Suisse and Wells Fargo Securities are acting as bookrunners, and Guggenheim Securities, Mizuho Securities, Raymond James, SunTrust Robinson Humphrey and Wedbush PacGrow are acting as co-managers for the offering.

This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor will there be any sale of, these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or other jurisdiction.

About TESARO
TESARO is an oncology-focused biopharmaceutical company devoted to providing transformative therapies to people bravely facing cancer.